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Objectives
The Post Synaptic density protein-95/Drosophila disc
large/Zonula occludens (PDZ) domain binding motif of
human papillomavirus (HPV) E6 correlates with malig-
nant transformation for high risk HPV. Recent evidence in
our lab has shown that HPV16 E6 binds and degrades
PTPN13 in a PDZ binding motif-dependent manner in
HPV-positive head and neck squamous cell cancer. The
loss of PTPN13 results in invasive growth when combined
with Ras expression. The purpose of this study is to inves-
tigate PTPN13 expression in normal and malignant cervi-
cal epithelial cells, and to evaluate its role in cervical
cancer.
Methods
PTPN13 expression was measured by Western blotting in
primary cultures of normal and high-risk HPV-infected
human cervix and foreskin keratinocytes, in non-tumori-
genic HPV 31b positive cells, in HPV positive (CaSki,
SiHa) and HPV-negative (C-33A) cervical carcinoma cell
lines. Immunohistochemistry with PTPN13 (C-20): sc-
1138 antibody was performed on cervical tissue speci-
mens. Primary human cervical cultures and C33A cells
were transduced with recombinant adenovirus containing
HPV16 E6, E7, and mutant lacking the PDZ domain bind-
ing motif (E6Δ146–151). SiHa and Caski cells were trans-
fected with plasmid containing PTPN13. PTPN13 loss was
induced in C33A cells using shRNA strategy. Morphologic
features, in vitro growth rate, and anchorage independent
growth were evaluated. RTPCR was used to measure E6
and E6* expression.
Results
Normal cervical epithelial cells, foreskin keratinocytes
and the HPV-negative C-33A cancer cell line express
PTPN13. HPV-positive cancer cell lines, as well as cervical
and foreskin epithelial cells containing HPV 16, 18, 31
show significant loss of PTPN13 expression. Cells trans-
duced with HPV16 E6Δ146–151/E7 do not survive in
vitro compared to cells transduced with HPV E6/E7.
PTPN13 loss is E6 PDZ dependent and appears to be asso-
ciated with integration of E6/E7 into the host genome. Re-
establishment of PTPN13 in SiHa and Caski cells
decreased colony formation efficiency in soft agar by 21(p
= 0.0031) and 68 percent(p = 0.0001) respectively. Loss of
PTPN13 via shRNA in C33A cell line increases its colony
formation efficiency 133 times (p = 0.0001) in soft agar.
Conclusion
PTPN13 may play an important role as a tumor suppres-
sor in HPV-mediated cervical carcinogenesis. Understand-
ing of this PDZ dependent mechanism may lead to
development of targeted molecular therapy against HPV-
positive cervical cancer.
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